Adipotide: Research & Studies
Scientific evidence, clinical trials, and research findings
📌TL;DR
- •4 clinical studies cited
- •Overall evidence level: low
- •6 research gaps identified
Research Studies
Reversal of obesity by targeted ablation of adipose tissue
Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W (2004) • Nature Medicine
Foundational study demonstrating that a peptide motif (CKGGRAKDC) homes to white fat vasculature and, when fused to a proapoptotic sequence, reverses obesity in mice through targeted ablation of adipose tissue.
Key Findings
- Identified CKGGRAKDC via in vivo phage display as homing to white fat vasculature
- Targeted peptidomimetic caused ~30% weight reduction in obese mice over 4 weeks
- Selective ablation of white adipose tissue with minimal off-target effects
Limitations: Mouse model onlyShort treatment durationLimited safety characterization
Peptide designed to elicit apoptosis in adipose tissue endothelium reduces food intake and body weight
Kim DH, Woods SC, Seeley RJ (2010) • Diabetes
Demonstrated that the adipose-targeting proapoptotic peptide reduces food intake and body weight in mice on a high-fat diet, reversing obesity within 27 days.
Key Findings
- Complete reversal of obesity within 27 days in high-fat diet mice
- Significant reduction in food intake
- Effects observed independent of leptin signaling
Limitations: Mouse modelMechanism of food intake reduction not fully characterized
A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys
Barnhart KF, Christianson DR, Hanley PW, Driessen WHP, Bernacky BJ, Baze WB, Wen S, Tian M, Ma J, Kolonin MG, Saha PK, Do KA, Hulvat JF, Gelovani JG, Chan L, Arap W, Pasqualini R (2011) • Science Translational Medicine
Landmark primate study showing that adipotide causes weight loss and improved insulin resistance in spontaneously obese rhesus monkeys, with 38.7% reduction in total body fat confirmed by MRI and DEXA.
Key Findings
- 38.7% decrease in total body fat percentage
- Approximately 50% reduction in insulin requirements
- Improved insulin resistance confirmed by metabolic testing
- White adipose tissue reduction confirmed by MRI and DEXA
Limitations: Reversible renal injury observed as primary side effectSmall sample sizeNon-human primate model
Rapid and weight-independent improvement of glucose tolerance induced by a peptide designed to elicit apoptosis in adipose tissue endothelium
Kim DH, Sartor MA, Bain JR, Sandoval D, Stevens RD, Medvedovic M, Newgard CB, Woods SC, Seeley RJ (2012) • Diabetes
Demonstrated that adipotide rapidly improves glucose tolerance in obese mice independent of weight loss, with decreased serum insulin and triglycerides and changes in mitochondrial and lipid metabolism gene expression.
Key Findings
- Rapid glucose tolerance improvement independent of weight loss
- Decreased serum insulin and triglycerides
- Gene expression changes in mitochondrial pathways and lipid metabolism
- Novel role of adipose vasculature in metabolic homeostasis
Limitations: Mouse modelMechanism of weight-independent metabolic effects needs further study
Unlock full research citations
Free access to all clinical studies, citations, and evidence summaries.
150+ peptide profiles · 30+ comparisons · 18 research tools
Community Experience Data
See how community outcomes align with (or diverge from) the research findings above.
Based on 25+ community reports
View community protocolsExplore research gaps across all peptides → | View clinical trial pipeline →
🔍Research Gaps & Future Directions
- •No human clinical trials conducted
- •Renal toxicity limits clinical translation
- •Long-term effects unknown
- •Optimal dosing not established
- •Drug interaction profile not characterized
- •No formal toxicology studies published
Research Overview#
Adipotide (FTPP) has been investigated exclusively in preclinical models, with research spanning mouse and non-human primate studies. The evidence base, while scientifically compelling, remains limited to animal data with no human clinical trials conducted. All published studies originate primarily from the laboratory group that developed the compound.
Foundational Discovery#
The concept of targeting adipose tissue vasculature for obesity treatment was first demonstrated by Kolonin et al. in 2004. Using in vivo phage display, the researchers screened a random peptide library in mice and identified the cyclic motif CKGGRAKDC as having selective affinity for the blood vessels supplying white adipose tissue. The target receptor was identified as prohibitin, a protein differentially expressed on adipose endothelial cell surfaces.
When this homing peptide was fused to the proapoptotic sequence D(KLAKLAK)2, systemic administration to genetically obese mice resulted in selective destruction of white adipose tissue vasculature and approximately 30% reduction in body weight over 4 weeks. The treatment normalized body mass index and improved metabolic parameters without detectable toxicity in that initial study.
Metabolic Characterization Studies#
Kim, Woods, and Seeley (2010) expanded on the original findings by examining the compound in diet-induced obese mice on a high-fat diet. Their results showed complete reversal of obesity within 27 days, accompanied by a reduction in food intake. The food intake reduction was unexpected, as the proposed mechanism involves direct adipose destruction rather than central appetite regulation. This finding suggested secondary metabolic signaling effects, possibly mediated by adipokine changes resulting from fat mass reduction.
The same group published a follow-up study in 2012 demonstrating that adipotide rapidly improved glucose tolerance in obese mice in a weight-independent manner. The improvement in glucose metabolism occurred before significant weight loss, suggesting that disruption of adipose vasculature may release metabolic signals that enhance insulin sensitivity. Gene expression profiling revealed changes in mitochondrial pathways and lipid metabolism genes, pointing to a broader metabolic impact than simple fat reduction.
Primate Translation Study#
The most significant study in the adipotide literature is the 2011 primate trial by Barnhart et al., which evaluated the compound in spontaneously obese rhesus monkeys. This study is notable for being one of very few peptide-based anti-obesity interventions tested in non-human primates.
Key findings from the primate study included a 38.7% decrease in total body fat percentage from baseline to the end of the recovery period, confirmed by both MRI and dual-energy X-ray absorptiometry (DEXA). Treated animals showed approximately 50% reduction in insulin requirements, indicating substantial improvement in insulin resistance. The changes were observed over the treatment period with some continued improvement during recovery.
However, the study also identified the primary safety concern: predictable, dose-dependent, and reversible renal injury. The nephrotoxicity manifested as altered tubular function and was attributed to the proapoptotic domain affecting renal tubular endothelium, which shares some surface markers with adipose vasculature.
Evidence Quality Assessment#
The overall evidence for adipotide is classified as low quality due to several limitations. All data come from animal models, with the strongest evidence from a single primate study. The research has been conducted predominantly by the group that developed the compound, limiting independent validation. The renal toxicity observed in primates represents a significant barrier to clinical translation. No formal dose-finding, toxicology, or pharmacokinetic studies have been published. The compound has not entered any phase of clinical trial development.
Comparison with Other Anti-Obesity Approaches#
Unlike GLP-1 receptor agonists or amylin analogs that work through appetite regulation and metabolic signaling, adipotide operates through a fundamentally different mechanism of direct vascular destruction. This unique approach provides proof of concept for targeted tissue ablation as an anti-obesity strategy but also introduces unique safety challenges. The irreversibility of adipose tissue destruction and the risk of off-target vascular effects distinguish adipotide from reversible pharmacological interventions.
Future Research Directions#
Several areas require further investigation before adipotide could advance toward clinical development. These include the development of modified versions with reduced renal toxicity, characterization of the long-term effects of adipose tissue ablation on endocrine function, formal toxicology and pharmacokinetic studies, understanding of the weight-independent metabolic effects, and assessment of the immune response to repeated administration.
Related Reading#
Where to Find Adipotide
Research-grade suppliers verified by our scoring methodology.
Frequently Asked Questions About Adipotide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.